Suvretta Capital Management’s Legend Biotech LEGN Stock Holding History

Suvretta Capital Management’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$204M	Sell	7,070,000 -511,029	-7%	-$13.8M	3.73%	4
2026 Q1	$137M	Buy	7,581,029 +972,400	+15%	+$18.5M	3.5%	6
2025 Q4	$144M	Buy	6,608,629 +2,790,620	+73%	+$79.9M	2.94%	5
2025 Q3	$125M	Buy	3,818,009 +44,000	+1%	+$1.62M	3.19%	5
2025 Q2	$134M	Buy	3,774,009 +24,044	+0.6%	+$779K	4.04%	5
2025 Q1	$127M	Buy	3,749,965 +253,731	+7%	+$9.1M	4.72%	5
2024 Q4	$114M	Buy	+3,496,234	New	+$145M	3.88%	5
2022 Q4	–	Sell	-274,200	Closed	-$11.2M	–	96
2022 Q3	$11.2M	Buy	+274,200	New	+$12.9M	0.46%	48
2020 Q3	–	Sell	-100,000	Closed	-$4.26M	–	108
2020 Q2	$4.26M	Buy	+100,000	New	+$3.91M	0.09%	57

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Suvretta Capital Management's LEGN Position: Q2 2026 in Review

Suvretta Capital Management reduced its Legend Biotech (LEGN) stake by 6.7% in Q2 2026, selling an estimated $13.8M and leaving 7,070,000 shares worth $204M. The position accounts for 3.73% of the portfolio, ranked #4.

Suvretta Capital Management first reported a position in LEGN in Q2 2020 and has held it in 9 quarters since. 218 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

Suvretta Capital Management held 7,070,000 shares of Legend Biotech worth $204M as of Q2 2026.
Suvretta Capital Management sold 511,029 Legend Biotech shares in Q2 2026, an estimated $13.8M.
Legend Biotech made up 3.73% of Suvretta Capital Management's portfolio in Q2 2026, its #4 holding.
Suvretta Capital Management first reported a position in Legend Biotech in Q2 2020 and has held it in 9 quarters since.
218 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Suvretta Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.